Loading organizations...
§ Corporate Venture Capital · San Francisco, CA, USA
Corporate venture capital firm investing in early- and late-stage biotechnology companies, focused on human therapeutics and digital health.
Amgen Ventures is the corporate venture capital arm of global biopharmaceutical company Amgen, investing in early- and late-stage biotechnology startups from its headquarters in Thousand Oaks, California. The firm focuses its investments on human therapeutics, digital health solutions, and next-generation drug discovery platforms to generate both financial and strategic returns. Since its inception, the fund has invested in over 60 emerging life sciences companies, typically writing initial checks ranging from $2 million to $3 million per startup. The firm's portfolio includes notable biotechnology enterprises such as Arrakis Therapeutics, Plexium, and Neumora Therapeutics, which received a $100 million equity investment alongside a strategic collaboration. Additionally, the firm participated in a $370 million Series B funding round for artificial intelligence-driven protein therapeutics developer Generate Biomedicines. Amgen Ventures was founded in 2004 by its parent corporation, Amgen.
Key people at Amgen Ventures.
Amgen Ventures has more than 26 tracked investments across 25 companies. The latest tracked deal is $140.0M Series B in AAVantgarde Bio in November 2025.
Key people at Amgen Ventures.
Amgen Ventures is the venture capital arm of Amgen, a global leader in biotechnology. Established in 2004, Amgen Ventures is headquartered in California and focuses on investing in early- to late-stage biotechnology, therapeutics, and health technology companies. Its mission is to accelerate innovation in healthcare by supporting startups whose scientific and therapeutic goals align with Amgen’s strategic priorities. The firm’s investment philosophy centers on identifying transformative science and enabling its translation into real-world therapies, with a particular emphasis on unmet medical needs. Amgen Ventures has made over 70 investments and committed more than $1 billion in equity, supporting healthcare innovation across the entire development spectrum. Its impact on the startup ecosystem is amplified by access to Amgen’s scientific expertise, mentorship, and global network, helping promising life sciences ventures scale and succeed.
Amgen Ventures was founded in 2004 as a strategic extension of Amgen’s commitment to advancing biotechnology and healthcare innovation. As a subsidiary of Amgen, the firm was created to identify and nurture emerging companies working on breakthrough therapies and technologies. Over the years, Amgen Ventures has evolved from a primarily internal innovation engine to a recognized external investor, actively shaping the biotech startup landscape. The team is composed of seasoned professionals with deep scientific and business development backgrounds, many of whom have played pivotal roles in Amgen’s own growth. Amgen Ventures’ close alignment with Amgen’s Business Development group and its Start-Up Network Program has enabled it to provide not just capital, but also scientific guidance, mentorship, and access to Amgen’s global resources.
Amgen Ventures is riding the wave of rapid advancements in biotechnology, genomics, and personalized medicine. The timing is critical, as the healthcare industry faces increasing demand for innovative therapies and digital health solutions. Amgen Ventures is well-positioned to capitalize on these trends, leveraging its deep scientific roots and strategic focus to identify and support the next generation of biotech leaders. The firm’s influence extends beyond its portfolio, shaping the broader ecosystem by fostering collaboration between startups, academia, and industry. As the boundaries between biotech, therapeutics, and health tech continue to blur, Amgen Ventures is helping to drive the convergence of science and technology in healthcare.
Amgen Ventures is poised to remain a key player in the biotech investment landscape, with a growing emphasis on digital health, AI-driven drug discovery, and novel therapeutic modalities. The firm’s ability to combine capital with scientific expertise and strategic guidance will continue to attract top-tier startups and drive innovation in healthcare. As the demand for personalized and precision medicine grows, Amgen Ventures is likely to expand its portfolio into new therapeutic areas and geographies, further solidifying its role as a catalyst for healthcare transformation. The future of biotech is bright, and Amgen Ventures is at the forefront, shaping the next chapter of medical breakthroughs.
